Active, not recruitingPHASE1, PHASE2NCT04179162

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Studying Muscular tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Eugene Pietzak, MD
Memorial Sloan Kettering Cancer Center
Intervention
Bacillus Calmette-Guérin (BCG)(drug)
Enrollment
54 enrolled
Eligibility
18 years · All sexes
Timeline
20192026

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04179162 on ClinicalTrials.gov

Other trials for Muscular tumor

Additional recruiting or active studies for the same condition.

See all trials for Muscular tumor

← Back to all trials